Laboratory of Biomedical Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, 18 Kremlyovskaya Street, Kazan 420008, Russia.
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.
Cells. 2024 Jul 30;13(15):1282. doi: 10.3390/cells13151282.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints. Although much remains unknown about the pathogenesis of RA, there is evidence that impaired immune tolerance and the development of RA are related. And it is precisely the restoration of immune tolerance at the site of the inflammation that is the ultimate goal of the treatment of RA. Over the past few decades, significant progress has been made in the treatment of RA, with higher rates of disease remission and improved long-term outcomes. Unfortunately, despite these successes, the proportion of patients with persistent, difficult-to-treat disease remains high, and the task of improving our understanding of the basic mechanisms of disease development and developing new ways to treat RA remains relevant. This review focuses on describing new treatments for RA, including cell therapies and gene editing technologies that have shown potential in preclinical and early clinical trials. In addition, we discuss the opportunities and limitations associated with the use of these new approaches in the treatment of RA.
类风湿关节炎(RA)是一种以关节慢性炎症为特征的自身免疫性疾病。尽管 RA 的发病机制仍有许多未知之处,但有证据表明,免疫耐受受损和 RA 的发展有关。而正是在炎症部位恢复免疫耐受,才是 RA 治疗的最终目标。在过去的几十年中,RA 的治疗取得了重大进展,疾病缓解率更高,长期预后得到改善。不幸的是,尽管取得了这些成功,但仍有很大比例的患者存在持续性、难以治疗的疾病,因此,提高我们对疾病发展基本机制的理解并开发治疗 RA 的新方法仍然具有重要意义。这篇综述重点描述了 RA 的新治疗方法,包括细胞疗法和基因编辑技术,这些方法在临床前和早期临床试验中显示出了潜力。此外,我们还讨论了在 RA 治疗中使用这些新方法的机会和限制。